Stocks Of Several Vaccine Makers Dropped In Pre-Holiday Session

Pfizer Inc (PFE) was down -0.45 percent to $37.27 whereas it’s German partner BioNTech SE (BNTX) fell by 3.10 percent to $96.96. On Thursday, the French High Health Authority (HAS) approved the COVID-19 vaccine developed by Pfizer and BioNTech laboratories to be used, the last regulatory move prior to the start of vaccination in France on Sunday. “The BNT162b2 vaccine can be used in people 16 years of age and older, including older people, due to its efficacy and satisfactory tolerance profile,” the HAS said in an opinion on the vaccination strategy. The HAS said, “This opinion will be reviewed in light of the evolution of knowledge, particularly in light of the full results of the Phase 3 trials,”


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


On Monday, the European Commission gave the green light to the use of the vaccine hours after giving a favorable opinion to the European Medicines Agency (EMA). It is now up to the Euro-bloc member countries to make their policy clear and to manage the national level vaccination campaign.

A number of European countries, including Austria, Germany, Italy and France, have confirmed that they plan to receive the first doses of the vaccine as of Sunday. French Health Minister Olivier Véran said Tuesday that the first recipients of the vaccine will be the occupants of two or three care homes.

Moderna Inc (MRNA) was down -5.33 percent to end the shorter session at $123.39. The biotechnology firm considered that its COVID-19 vaccine also protects against the virus variant found in Britain and announced that tests to validate it would be performed.

The other biotechnology firm Altimmune Inc (ALT) having in efforts of Covid vaccine has to face a timely failure when the FDA on Thursday postponed to application for human testing of the vaccine candidate. The FDA’s decision caused the firm to saw a fall of -9.27 percent in its stock price on the day which at the end of session was at $11.45.

LEAVE A REPLY

Please enter your comment!
Please enter your name here